Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

Provided By GlobeNewswire

Last update: Aug 1, 2023

TORONTO and HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the issuance of U.S. Patent No. 11,680,090, titled "Interleukin-2 Fusion Proteins and Uses Thereof." The patent further strengthens Medicenna's intellectual property around its BiSKIT™ (Bifunctional SuperKine for ImmunoTherapy) platform.